Plasma rich in growth factors versus Mitomycin C in photorefractive keratectomy.

ABSTRACT: To evaluate the efficacy and safety of plasma rich in growth factors (PRGF) in photorefractive keratectomy (PRK) versus Mitomycin C (MMC).This is a comparative, longitudinal and retrospective case-control study (MMC vs PRGF), in patients with a spherical correction from -0.25 to -8.00 D and cylinder correction from -0.25 to -3.00. The uncorrected distance visual acuity (UDVA), refractive efficacy and safety indices, and changes in endothelial cell density were evaluated. The predictability was assessed with the postoperative manifest spherical equivalent.Forty-four patients (72 eyes) were treated with MMC and twenty-five patients (45 eyes) with PRGF. The final UDVA (LogMar) in MMC was 0.029 ±â€Š0.065 and in PRGF it was 0.028 ±â€Š0.048 (p = 0.383). The efficacy index for MMC was 0.98 ±â€Š0.10 and 1.10 ±â€Š0.46 for patients treated with PRGF (p = 0.062). The safety index for MMC was 1.03 ±â€Š0.11 and 1.12 ±â€Š0.46 (p = 0.158) for PRGF group. The change percentage of endothelial cell density was 0.9 ±â€Š11.6 for MMC and 4.3 ±â€Š13.1 for PRGF (p = 0.593). The predictability for MMC was 92.1% and for the PRGF was 91.9% (p = 0.976). Hyperemia, eye pain and superficial keratitis were observed in 11.1% of the MMC group; no adverse events were observed with the PRGF.The use of PRGF in PRK surgery is as effective as MMC. The PRGF shows a better safety profile than MMC for its intraoperative use in PRK.

Plasma Rich in Growth Factors for the Treatment of Dry Eye after LASIK Surgery.

PURPOSE: The aim of this study was to evaluate the use of plasma rich in growth factors (PRGF) eye drops in patients with dry eye disease after laser-assisted in situ keratomileusis (LASIK) surgery. MATERIAL AND METHODS: This is a longitudinal, retrospective, comparative, and descriptive study of 77 eyes of 42 patients with dry eye disease following LASIK surgery. This study was designed to evaluate the efficacy of PRGF treatment compared to conventional therapy (control group). Outcome measures including signs and symptoms of dry eye disease were evaluated before and after treatment. The percentage of change before and after treatment for each clinical variable measured was compared between both groups. RESULTS: There were 1-4 treatment cycles with PRGF eye drops (1 cycle = 6 weeks). Results showed a statistically significant improvement in the Ocular Surface Disease Index (38.12%), visual analogue scale scores for frequency (41.89%) and severity (42.47%), and the Schirmer test scores (88.98%) after PRGF treatment (p < 0.05). No adverse events were reported after PRGF treatment. CONCLUSIONS: These results suggest that PRGF eye drops are effective for the improvement of dry eye symptoms in patients who underwent LASIK surgery in comparison to the conventional therapy. The treatment with PRGF is an alternative for patients who suffer from postoperative dry eye.

Niveles de hemoglobina glicosilada y velocidad de progresión de retinopatía diabética. Análisis de supervivencia en pacientes del Servicio de Oftalmología del Hospital General de las Fuerzas Armadas Quito, enero 2004 ­ diciembre 2008 / Glycosylated hemoglobin levels and progression rate of Diabetic retinopathy. Survival analysis in patients of Ophthalmology Service of the General Hospital of the Armed Forces Quito, January 2004 - December 2008

Introducción: En Ecuador en los últimos diez años se ha producido un notable incremento en la prevalencia de diabetes mellitus del 3 al 13.3%, convirtiéndola en el trastorno discapacitante más frecuente y de mayor severidad que enfrenta la población ecuatoriana. Uno de los órganos blanco afectados por esta enfermedad es el ojo, en particular la retina, por lo que se han descrito diferencias en el comportamiento de la retinopatía diabética a través del tiempo según el control metabólico. Objetivo: Determinar la relación entre la severidad de la retinopatía diabética y el tiempo de su progresión con los niveles de hemoglobina glicosilada a través del tiempo. Métodos: Análisis de supervivencia de 89 pacientes diabéticos tipo 2 que acudieron al Servicio de Oftalmología del Hospital General de las Fuerzas Armadas en Quito, desde enero del 2004 a diciembre del 2008. Resultados: La prevalencia de retinopatía diabética al inicio del estudio fue de 50.6%, y 79.8% al final del estudio. Se observó que un buen control glicémico puede ser un factor de protección para la progresión de retinopatía diabética (OR 0.27; IC 95%: 0.10 a 0.76). La progresión de retinopatía diabética no proliferativa a retinopatía diabética proliferativa se vio en 33% de los pacientes en 5 años. La cuarta parte de los pacientes que no presentaba retinopatía diabética al inicio del estudio la desarrolló dentro del periodo de cinco años del estudio y el 100% de los pacientes con retinopatía diabética no proliferativa severa tuvieron una progresión a retinopatía diabética proliferativa. Conclusión: Un buen control glicémico retrasa más no impide la presencia de retinopatía diabética. Los pacientes con mayor tiempo de evolución de la enfermedad tienen peor control de la glicemia.

Introduction: In Ecuador in the last ten years there has been a remarkable increase in the prevalence of diabetes mellitus from 3 to 13.3%, making it the most frequent and most severe disabling disorder facing the population Ecuadorian One of the white organs affected by this disease is the eye, in particular retina, so differences in the behavior of the diabetic retinopathy over time according to metabolic control. Objective: To determine the relationship between the severity of diabetic retinopathy and the time of its progression with glycosylated hemoglobin levels through the weather. Methods: Survival analysis of 89 type 2 diabetic patients who attended to the Ophthalmology Service of the General Hospital of the Armed Forces in Quito, from January 2004 to December 2008. Results: The prevalence of diabetic retinopathy at the start of the study was 50.6%, and 79.8% at the end of the study. It was observed that a good glycemic control can be a protection factor for the progression of diabetic retinopathy (OR 0.27; 95% CI: 0.10 to 0.76). The progression of non-proliferative diabetic retinopathy to diabetic retinopathy Proliferative was seen in 33% of patients in 5 years. The fourth part of the patients who did not have diabetic retinopathy at the beginning of the study, developed it within the Five-year study period and 100% of patients with diabetic retinopathy Severe nonproliferative had a progression to proliferative diabetic retinopathy. Conclusion: A good glycemic control delays more does not prevent the presence of Diabetic retinopathy. Patients with the longest evolution of the disease They have worse glycemic control.